What are the dosing recommendations, contraindications, precautions, and common adverse effects for doxepin?

Doxepin: Dosing, Contraindications, Precautions, and Adverse Effects

For chronic insomnia, use low-dose doxepin at 3 mg or 6 mg as a short course only in patients unable or unwilling to receive cognitive behavioral therapy for insomnia (CBT-I), which remains the superior first-line treatment. 1

Dosing Recommendations

For Insomnia (Low-Dose Formulation)

• Start with 3 mg or 6 mg taken 30 minutes before bedtime 1
• The 1 mg dose showed variable efficacy in older adults 1
• Both 3 mg and 6 mg doses demonstrated equivalent efficacy for sleep maintenance 2
• Maximum recommended dose: 6 mg for insomnia indication
• Use for the shortest duration possible given lack of long-term safety data 1

For Depression/Anxiety (Standard Tricyclic Dosing)

• Initial dose: 75 mg daily for mild to moderate illness 3
• Optimal range: 75-150 mg daily 3
• Severe cases: May increase gradually to 300 mg daily maximum 3
• Very mild symptoms: 25-50 mg daily may suffice 3
• Once-daily dosing at bedtime is acceptable up to 150 mg (higher doses require divided dosing) 3
• The 150 mg capsule is for maintenance only, not treatment initiation 3

Critical dosing consideration: Significant interindividual variability exists in doxepin plasma levels at identical doses due to genetic polymorphisms (particularly CYP2D6), drug interactions, and patient factors 4. Blood level monitoring can optimize dosing in treatment-resistant cases 4.

Contraindications

Absolute Contraindications

• MAO inhibitor use within 14 days (potentially fatal interactions) 3
• Known hypersensitivity to doxepin
• Acute recovery phase post-myocardial infarction 3
• Untreated narrow-angle glaucoma (risk of angle-closure attack) 3

Relative Contraindications/High-Risk Populations

• Urinary retention or severe prostatic hypertrophy (anticholinergic effects) 3
• Severe hepatic or renal impairment 3
• Concurrent use with other CNS depressants, especially alcohol 3

Precautions and Warnings

Black Box Warning: Suicidality

All patients, particularly those under 24 years, require close monitoring for worsening depression, suicidal ideation, and behavioral changes, especially during the first few months of treatment or dose adjustments 3. Prescribe the smallest feasible quantity 3.

Critical Monitoring Requirements

• Screen for bipolar disorder before initiating treatment - antidepressant monotherapy may precipitate manic episodes 3
• Monitor for emergence of: anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania 3
• Daily observation by families/caregivers is recommended initially 3

Elderly Patients

• Start at low doses and titrate cautiously due to increased risk of confusion, oversedation, falls, and cognitive impairment 3
• Higher likelihood of decreased renal function affects drug clearance 3
• For insomnia in elderly: 3 mg or 6 mg doses are well-tolerated and effective 2

Drug Interactions

• Cimetidine: Significantly elevates tricyclic levels, causing severe anticholinergic toxicity 3
• CYP2D6 inhibitors (SSRIs, quinidine, antiarrhythmics): Increase doxepin levels up to 8-fold 3
• Alcohol: Potentiates CNS depression and overdose risk 3
• Tolazamide: Case report of severe hypoglycemia in diabetic patients 3

Pregnancy and Lactation

• No established safety in pregnancy despite animal studies showing no harm 3
• Apnea and drowsiness reported in nursing infants - use caution with breastfeeding 3

Pediatric Use

• Not recommended under age 12 - safety not established 3
• Balance potential risks against clinical need in adolescents 3

Common Adverse Effects

Most Frequent (Low-Dose for Insomnia)

• Somnolence and headache are most common 5, 6
• Adverse event rates comparable to placebo at 3-6 mg doses 1, 2
• No significant next-day residual effects at low doses 5, 2
• No anticholinergic effects or memory impairment at low doses 2

Standard Tricyclic Doses (Depression/Anxiety)

Anticholinergic effects (most common):

• Dry mouth (most frequent) 3, 7
• Blurred vision 3
• Constipation 3
• Urinary retention 3

CNS effects:

• Drowsiness (most common, typically resolves with continued therapy) 3
• Confusion, disorientation, hallucinations 3
• Seizures, tremor, extrapyramidal symptoms 3

Cardiovascular:

• Hypotension, hypertension, tachycardia (occasional) 3
• Lower risk of postural hypotension compared to other tricyclics 7
• Cardiotoxicity in overdose similar to other tricyclics 7

Other notable effects:

• Weight gain 3
• Dizziness, tinnitus 3
• Sexual dysfunction (altered libido) 3
• Withdrawal symptoms with abrupt discontinuation (gradual taper required) 3

Serious but Rare

• Bone marrow depression (agranulocytosis, leukopenia, thrombocytopenia) 3
• Angle-closure glaucoma 3
• SIADH 3
• Drug abuse potential identified in pharmacovigilance data 8

Clinical Pearls

For insomnia management: The 2019 VA/DoD guidelines emphasize that CBT-I demonstrates superior long-term outcomes compared to pharmacotherapy 1. Low-dose doxepin should be reserved for patients who cannot access or refuse behavioral interventions.

Therapeutic timeline: Anti-anxiety effects appear before antidepressant effects; optimal antidepressant response may require 2-3 weeks 3.

Overdose risk: Deaths occur with tricyclic overdoses - monitor ECG for QRS widening ≥0.10 seconds as severity indicator. Treat with sodium bicarbonate to maintain pH 7.45-7.55 3.

Advantage over benzodiazepines: Guidelines explicitly recommend against benzodiazepines for chronic insomnia due to dependency, falls, cognitive impairment, and respiratory depression risks that substantially outweigh benefits 1.